Fish oil benefits: what human trials found, condition by condition

Heart disease, triglycerides and blood pressure

Fish oil's reputation was built in cardiology, so that is where the evidence is deepest. A typical over-the-counter softgel supplies roughly 300-600 mg of EPA and DHA combined. Many of the positive results below used several times that. More background sits on our fish oil topic page.

Cardiovascular events. A Cochrane review pooled 86 trials and 162,796 people, with doses from 0.5 g to more than 5 g a day. It found little or no effect on death, cardiovascular events, stroke or arrhythmia, and no difference by dose. This is the strongest evidence in the field, and it is a null result.

Individual trials complicate the picture. In 11,324 people who had recently had a heart attack, 1 g a day lowered a composite of death, nonfatal heart attack and stroke by 10-15% over 3.5 years. Pooled with 85 other trials, that benefit largely disappeared. In REDUCE-IT, 4 g a day of a purified prescription EPA drug cut cardiovascular events from 22.0% to 17.2% over about five years in 8,179 people already treated for cardiovascular disease or diabetes. That was a drug trial in a high-risk group, not a test of a softgel.

Atrial fibrillation. Across seven large trials (81,210 people), marine omega-3 was linked to more atrial fibrillation. The hazard ratio was 1.25 overall, 1.12 at 1 g a day or less, and 1.49 above 1 g. REDUCE-IT also saw more hospitalizations for the arrhythmia.

Triglycerides and cholesterol. A 2019 American Heart Association advisory concluded that prescription omega-3 at 4 g a day lowers triglycerides by at least 30% in adults who already have high levels. That is the best-supported effect fish oil has. LDL cholesterol is a different story: a Cochrane review of 23 trials in type 2 diabetes (mean 3.5 g a day) found triglycerides fell while LDL rose slightly.

Blood pressure. A dose-response analysis of 71 trials (4,973 people) found the largest drops at 2-3 g a day of EPA plus DHA: about 2.6 mmHg systolic and 1.6-1.8 mmHg diastolic. An umbrella review of 10 meta-analyses averaged only 1.2 and 0.9 mmHg across all doses. The effect is real but small, and it is not a substitute for medication.

Depression, anxiety and stress

Depression. A 2021 Cochrane review of 35 studies found a small effect of omega-3 on depressive symptoms in adults with major depressive disorder. The reviewers rated it very low certainty and unlikely to be clinically meaningful, and remission and response rates did not differ from placebo. A 2019 meta-analysis of 26 trials (2,160 people) suggested the type matters: mostly-EPA products at 1 g a day of EPA or less were associated with fewer symptoms, while DHA-dominant products were not. That is a hypothesis worth testing, not a settled answer.

Anxiety. Two meta-analyses converge on a threshold. The 2018 review (19 trials) found a benefit only in trials using at least 2,000 mg a day, with no significant effect below that. A 2024 dose-response analysis of 23 trials found the same pattern and rated certainty very low. A 300-600 mg softgel sits well under the dose where either review saw anything.

Stress and cortisol. Three small trials exist, none repeated. In 138 sedentary, overweight midlife adults, 2.5 g a day for four months was linked to 19% lower cortisol during a lab stress test. In 64 pregnant women, 450 mg a day of DHA was linked to lower perceived stress and a smaller cortisol response. In 68 medical students, 2.5 g a day was associated with 20% fewer anxiety symptoms around exams. These are narrow groups and surrogate measures, so the evidence is weak.

Memory, dementia and ADHD

Cognitive decline and dementia. A Cochrane review of the three largest trials in cognitively healthy older adults (over 3,200 people, 6-40 months) found no cognitive benefit. No trial measured dementia incidence directly. A 2023 scoping review of 78 trials was more mixed: 43.6% reported a positive cognitive outcome, rising to 66.7% in people with mild cognitive impairment, at doses from 79 mg to 5,200 mg a day. Counting positive trials is a blunt tool, so this is suggestive at best.

Memory and focus. In 485 adults 55 and older with measured age-related decline, 900 mg a day of DHA for 24 weeks improved two memory measures but not working memory or executive function. A six-month trial in 86 older adults with memory complaints found no effect of DHA on any cognitive test. A 22-person pilot found DHA-rich oil raised brain blood flow during tasks, with no reported change in performance. Nothing here supports a focus claim in healthy people.

ADHD. A 2011 meta-analysis of 10 trials (699 children) found a small benefit. A larger 2023 analysis of 22 trials (1,789 children) found no significant overall effect, though trials lasting at least 4 months did show one, and higher EPA dose did not predict benefit. All of this research is in children; the ADHD evidence in more detail is a useful companion. The evidence is conflicting.

Inflammation and joint pain

A 2014 meta-analysis of 68 trials (4,601 people) found marine omega-3 lowered CRP, IL-6 and TNF-alpha in both healthy people and those with chronic disease. Longer supplementation produced larger effects, and the effect was weaker in people with a BMI above 30. That is a reasonably consistent lab signal.

Lower markers do not guarantee less pain. A 2024 meta-analysis of 23 placebo-controlled trials in rheumatoid arthritis found only a small, mostly non-significant effect on pain and joint counts (standardized mean difference -0.16), with very low to low certainty. A 2017 analysis of 42 arthritis trials found a small, significant pain benefit in rheumatoid arthritis but none in osteoarthritis, the more common cause of knee and hip pain.

Blood sugar, body weight and fatty liver

Blood sugar. A 2022 meta-analysis of 30 studies found omega-3 reduced fasting glucose and insulin resistance but not HbA1c, the marker used to track long-term control. The Cochrane review in people with type 2 diabetes found no effect on blood sugar at all. In 11 trials of women with PCOS (816 people), omega-3 lowered fasting glucose, insulin and HOMA-IR, more consistently in trials longer than 8 weeks. The evidence is mixed and depends on the population.

Weight. In 11 trials with 617 overweight or obese adults, body weight did not differ from placebo, though waist circumference and triglycerides fell. A 2025 analysis of 21 studies (673 adults) found that adding omega-3 to an exercise program reduced fat mass by about 1 kg more than exercise alone, with no extra change in weight, BMI or lean mass. It is not a weight-loss tool.

Fatty liver. The answer depends on how liver fat is measured. A review requiring CT or MRI imaging pooled four omega-3 trials and found no significant effect. A larger review of 18 trials in 1,424 people with diagnosed fatty liver, mostly using blood tests, reported improvements in liver fat estimates and enzymes. We would trust the imaging result more, but both bodies of evidence are small and variable.

Pregnancy, period pain and hot flashes

Pregnancy. A 2018 Cochrane review of 70 trials (19,927 women) found high-quality evidence that omega-3 lowered preterm birth before 37 weeks (13.4% to 11.9%) and before 34 weeks (4.6% to 2.7%). There was also a probable small increase in pregnancies lasting past 42 weeks. Doses and forms varied, so this is not a dosing recommendation; that conversation belongs with a clinician. This is the best-supported benefit outside triglycerides.

Menstrual pain. A 2024 meta-analysis of 12 trials (881 women and girls) found a large reduction in period pain and less painkiller use at 300-1,800 mg a day. The trials were mostly of neutral quality and results were not split by dose. Individual crossover trials used 1,800 mg a day (42 adolescents) and 755 mg a day (36 women). Promising, but built on small studies.

Hot flashes. A 2009 trial in 91 symptomatic women found about 1,500 mg a day of EPA-only omega-3 cut hot flash frequency more than placebo over 8 weeks, but not intensity or quality of life. The larger MsFLASH analysis (899 women) found 1.8 g a day of omega-3 made no difference to frequency or bother. The larger trial carries more weight, so the evidence leans negative.

Skin, sleep, migraine and cancer

Skin. Two small pilot trials found benefits: 5.4 g a day of DHA improved eczema severity over 8 weeks in 53 adults, and 2 g a day of EPA plus DHA reduced acne lesions over 10 weeks in 45 people. Neither has been confirmed in a larger study. A 24-woman single-blind pilot of a proprietary supplement reported 10% better skin elasticity, with no change in roughness. Very weak evidence.

Sleep. A systematic review of 20 studies found improvements in infants and in children with existing sleep problems, but no effect on adults' sleep duration, latency, efficiency, quality or insomnia severity. Migraine. A 2018 meta-analysis of 13 trials found no effect on frequency or severity, but attacks were about 3.44 hours shorter. A 2025 analysis of 22 trials found no significant effect on any migraine outcome. Diabetic neuropathy. A 2025 Cochrane review found only two small trials (87 people), with low to very low certainty and little to no effect.

Cancer. In the VITAL trial (25,871 adults, 1 g a day, median 5.3 years), invasive cancer and cancer deaths did not differ from placebo. A separate observational study linked higher blood omega-3 levels to more prostate cancer, but it measured blood levels, not supplements, and the randomized trial carries more weight. Neither benefit nor harm is supported.

Side effects, absorption and a side-by-side view

Across 21 trials of prescription-strength omega-3 (24,460 people), fishy aftertaste and skin reactions were more common than with placebo, and EPA-plus-DHA products caused more burping and nausea. No clear serious adverse events turned up. A review found fish oil has a weak blood-thinning effect that is more noticeable alongside antiplatelet drugs, and less so with warfarin, though fish oil alone was not linked to meaningfully more surgical bleeding.

Absorption is a modest lever. A small 1988 trial found a high-fat meal improved uptake, and a four-week trial with matched doses found no significant blood-level difference between ethyl ester, triglyceride and krill forms, though a manufacturer funded it. For more on that comparison, see fish oil forms compared.